

# COVID-19 Sex Hormones and Disease Severity



Are levels of circulating sex hormones related to COVID-19 severity?



## **Background**


Men are more likely than women to develop severe COVID-19. Whether this sex-specific risk is related to sex hormones (eg, testosterone and estradiol) and inflammation is not fully understood.



### Methods and Results

Prospective study of 152 patients in a Missouri hospital with SARS-CoV-2 infection confirmed by PCR from March to May 2020

### **Sex Hormones Levels and COVID-19 Severity**





Low levels of circulating testosterone were associated with severe COVID-19 in men but not in women.

For more information about Quest Diagnostics publications, please visit the Clinical Education Center at Education.QuestDiagnostics.com/Publications.



# **COVID-19**Sex Hormones and Disease Severity

# Article Title: Association of Circulating Sex Hormones with Inflammation and Disease Severity in Patients with COVID-19

Sandeep Dhindsa,<sup>1</sup> Nan Zhang,<sup>2</sup> Michael J McPhaul,<sup>3</sup> Zengru Wu,<sup>3</sup> Amit K Ghoshal,<sup>4</sup> Emma C Erlich,<sup>2</sup> Kartik Mani,<sup>2,5</sup> Gwendalyn J Randolph,<sup>2</sup> John R Edwards,<sup>2</sup> Philip A Mudd,<sup>2</sup> Abhinav Diwan<sup>2,5</sup>

<sup>1</sup>Saint Louis University School of Medicine, St. Louis, MO, USA; <sup>2</sup>Washington University School of Medicine, St. Louis, MO, USA; <sup>3</sup>Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA; <sup>4</sup>Quest Diagnostics Nichols Institute, Valencia, CA, USA; <sup>5</sup>John Cochran VA Medical Center, St. Louis, MO, USA

Citation: JAMA Netw Open. 2021;4(5):e2111398. doi:10.1001/jamanetworkopen.2021.11398

#### Background

- Men are more likely than women to develop severe COVID-19.1
- Whether sex hormones contribute to COVID-19 severity is unknown, although some studies have shown that men with low testosterone
  have chronically elevated levels of inflammatory mediators.<sup>2,3</sup>
- **Objective:** In this study, investigators examined the association of serum testosterone, estradiol, and insulin-like growth factor 1 (IGF-1) with COVID-19 severity.

#### Methods

- A prospective cohort study was conducted using serum samples from consecutive patients presenting with COVID-19 symptoms between March and May 2020 at the Barnes Jewish Hospital, St. Louis, MO; infection was confirmed by molecular testing.
- For comparison between patients with severe and mild COVID-19, levels of circulating sex hormones (ie, testosterone, estradiol, IGF-1) were measured on Day 0 (at presentation) and Day 3 of hospitalization.
  - Severe COVID-19 was defined by death due to COVID-19 or patients requiring ICU care, supplemental oxygen due to hypoxia, or mechanical ventilation.
  - Levels of inflammatory markers were also measured in a subset of patients on Day 0.

#### Results

- Among the 152 consecutive patients (90 men, 62 women) who presented with COVID-19, 73% (66/90) of men and 60% (37/62) of women had severe disease.
- Among men, median (interquartile range) testosterone levels were significantly lower in those with severe COVID-19 than in those with mild disease (all comparisons P<0.05):</li>
  - Hospital Day 0: 53 (8-114) ng/dL vs 151 (95-217) ng/dL
  - Hospital Day 3: 19 (6-68) ng/dL vs 111 (49-274) ng/dL
- Testosterone concentrations were also inversely associated with inflammatory markers (*P*<0.05) in men.
- Estradiol and IGF-1 concentrations were not associated with severe COVID-19 in men.
- Among women, sex hormone concentrations were similar in those with severe and mild COVID-19.

#### Conclusions

- These findings indicate that lower circulating testosterone levels are associated with severe COVID-19 and inflammation in men but not in women.
- Further studies will be needed to determine whether testosterone is a marker or cause of COVID-19 severity.

#### References

- 1. Peckham H, de Gruijter NM, Raine C, et al. Nat Commun. 2020;11:6317. doi:10.1038/s41467-020-19741-6
- 2. Bhatia V, Chaudhuri A, Tomar R, et al. Diabetes Care. 2006;29(10):2289-2294. doi:10. 2337/dc06-0637
- 3. Grossmann M, Thomas MC, Panagiotopoulos S, et al. J Clin Endocrinol Metab. 2008;93(5):1834-1840. doi:10.1210/jc.2007-2177